| The lipid and non-lipid effects of statins AS Wierzbicki, R Poston, A Ferro Pharmacology & therapeutics 99 (1), 95-112, 2003 | 354 | 2003 |
| S-Nitrosothiols: a class of nitric oxide-donor drugs H Al-Sa'Doni, A Ferro Clinical science 98 (5), 507-520, 2000 | 301 | 2000 |
| Hydrogen sulfide induces Keap1 S-sulfhydration and suppresses diabetes-accelerated atherosclerosis via Nrf2 activation L Xie, Y Gu, M Wen, S Zhao, W Wang, Y Ma, G Meng, Y Han, Y Wang, ... Diabetes 65 (10), 3171-3184, 2016 | 274 | 2016 |
| Pharmacogenetics of aspirin resistance: a comprehensive systematic review T Goodman, A Ferro, P Sharma British journal of clinical pharmacology 66 (2), 222-232, 2008 | 274 | 2008 |
| Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products X Biao, R Chibber, D Ruggiero, E Kohner, J Ritter, A Ferro The FASEB Journal 17 (10), 1289-1291, 2003 | 271 | 2003 |
| Monocyte-platelet interaction induces a pro-inflammatory phenotype in circulating monocytes G Passacquale, P Vamadevan, L Pereira, C Hamid, V Corrigall, A Ferro PloS one 6 (10), e25595, 2011 | 223 | 2011 |
| Platelet-derived nitric oxide signaling and regulation E Gkaliagkousi, J Ritter, A Ferro Circulation research 101 (7), 654-662, 2007 | 217 | 2007 |
| Activation of nitric oxide synthase by β2‐adrenoceptors in human umbilical vein endothelium in vitro A Ferro, LR Queen, RM Priest, B Xu, JM Ritter, L Poston, JPT Ward British journal of pharmacology 126 (8), 1872-1880, 1999 | 210 | 1999 |
| Mechanisms of aspirin resistance CN Floyd, A Ferro Pharmacology & therapeutics 141 (1), 69-78, 2014 | 209 | 2014 |
| A textbook of clinical pharmacology and therapeutics J Ritter, L Lewis, T Mant, A Ferro CRC Press, 2008 | 195 | 2008 |
| Nitric oxide signalling in the regulation of cardiovascular and platelet function E Gkaliagkousi, A Ferro Front Biosci 16 (1), 1873-97, 2011 | 160 | 2011 |
| Human endothelin receptors characterized using reverse transcriptase-polymerase chain reaction, in situ hybridization, and subtype-selective ligands BQ123 and BQ3020: evidence … AP Davenport, G O'Reilly, P Molenaar, JJ Maguire, RE Kuc, A Sharkey, ... Journal of cardiovascular pharmacology 22, S22-S25, 1993 | 156 | 1993 |
| Reaction of carnosine with aged proteins: another protective process? AR Hipkiss, C Brownson, MF Bertani, E Ruiz, A Ferro Annals of the New York Academy of Sciences 959 (1), 285-294, 2002 | 141 | 2002 |
| Increased expression of integrin-linked kinase attenuates left ventricular remodeling and improves cardiac function after myocardial infarction L Ding, L Dong, X Chen, L Zhang, X Xu, A Ferro, B Xu Circulation 120 (9), 764-773, 2009 | 114 | 2009 |
| Emerging role of hydrogen sulfide in hypertension and related cardiovascular diseases G Meng, Y Ma, L Xie, A Ferro, Y Ji British journal of pharmacology 172 (23), 5501-5511, 2015 | 113 | 2015 |
| Nitric oxide‐dependent β2‐adrenergic dilatation of rat aorta is mediated through activation of both protein kinase A and Akt A Ferro, M Coash, T Yamamoto, J Rob, Y Ji, L Queen British journal of pharmacology 143 (3), 397-403, 2004 | 110 | 2004 |
| SIRT3 mediates the antioxidant effect of hydrogen sulfide in endothelial cells L Xie, H Feng, S Li, G Meng, S Liu, X Tang, Y Ma, Y Han, Y Xiao, Y Gu, ... Antioxidants & redox signaling 24 (6), 329-343, 2016 | 109 | 2016 |
| Nitric oxide dysfunction in vascular endothelium and platelets: role in essential hypertension E Gkaliagkousi, S Douma, C Zamboulis, A Ferro Journal of hypertension 27 (12), 2310-2320, 2009 | 109 | 2009 |
| β2-Adrenoceptors Activate Nitric Oxide Synthase in Human Platelets LR Queen, B Xu, K Horinouchi, I Fisher, A Ferro Circulation Research 87 (1), 39-44, 2000 | 108 | 2000 |
| Celastrol prevents atherosclerosis via inhibiting LOX-1 and oxidative stress L Gu, W Bai, S Li, Y Zhang, Y Han, Y Gu, G Meng, L Xie, J Wang, Y Xiao, ... PloS one 8 (6), e65477, 2013 | 103 | 2013 |
